Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 14/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794039 | 0.88 | BTK (0.45) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL29676713 | 0.84 | IKBKE (0.47) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL16794044 | 0.84 | IKBKE (0.49) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL16794198 | 0.84 | BTK (0.65) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL29676766 | 0.82 | IKBKE (0.48) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL16794380 | 0.80 | IKBKE (0.51) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL20445711 | 0.80 | IKBKE (0.48) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL20054055 | 0.79 | IKBKE (0.43) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL20054019 | 0.79 | IKBKE (0.43) | IKBKETBK1BTKCCNT1CCNE1 | |
| SCHEMBL19557886 | 0.77 | IKBKE (0.60) | IKBKETBK1BTKCCNT1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-10-20 | — | — | US | disclosed |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | BIOGEN MA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | BIOGEN MA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2019-07-18 | — | — | US | disclosed |
| US-10081619-B2 | Biaryl inhibitors of bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| EP-3080103-B9 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3357921-A2 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Sunesis Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3080103-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
| EP-3080103-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089337-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089337-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | IKBKE 351/4885TBK1 266/4885BTK 2/4885 |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | ABL1, BTK, LYN | IKBKE 351/4885TBK1 266/4885BTK 2/4885 |
| US-10081619-B2 | Biaryl inhibitors of bruton's tyrosine kinase | ABL1, BTK, LYN | IKBKE 351/4885TBK1 266/4885BTK 2/4885 |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | IKBKE 351/4885TBK1 266/4885BTK 2/4885 |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | IKBKE 351/4885TBK1 266/4885BTK 2/4885 |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | IKBKE 351/4885TBK1 266/4885BTK 2/4885 |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | IKBKE 351/4885TBK1 266/4885BTK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.